Chemotherapy-Induced Myelosuppression in SCLC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Chemotherapy-Induced Myelosuppression in SCLC

Playback speed

10 seconds

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

By Dana-Farber Cancer Institute FEATURING Jacob Sands

611 views

November 8, 2021

Comments 0

Myelopreservation With the CDK4/6i Trilaciclib in Patients With SCLC…

UNC Lineberger Comprehensive Cancer Center

J. Weiss

497 views

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression in E…

Jerome Goldschmidt

513 views

Importance of Addressing Myelosuppression in Chemotherapy Patients

Edgardo Santos

184 views

Myelosuppression in ES-SCLC Therapy

Maen Hussein

242 views

Nebraska Oncology Society 2022 SCLC Management Updates

Nebraska Oncology Society

T. Leal

179 views

Treatment Landscape of SCLC

Edgardo Santos

189 views

Trilaciclib and the Economic Value of Multilineage Myeloprotection F…

Ivo Abraham

640 views

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolim…

ASCO 2022 Conference Coverage

J. Sands

510 views

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracra…

ASCO 2022 Conference Coverage

K. Gaebe

431 views

ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelos…

ASCO 2022 Conference Coverage

J. Goldschmidt

93 views

ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relap…

ASCO 2022 Conference Coverage

A. Navarro

253 views

Lecture Summary - ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Stud…

ASCO 2022 Conference Coverage

J. Sands

43 views

Lecture Summary - ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in…

ASCO 2022 Conference Coverage

K. Gaebe

47 views

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC …

ASCO 2022 Conference Coverage

A. Navarro

23 views